Annexon Reports $55.3 Million Net Loss in Q2 2026, Focuses on Late-Stage Programs

Annexon, Inc. reported a net loss of $55.3 million for the three months ended June 30, 2026, compared to a net loss of $49.2 million for the same period in 2025, marking a 13% increase in losses year-over-year. For the first half of 2026, the company recorded a net loss of $99.5 million, a slight improvement from the $103.5 million loss reported in the first half of 2025. Total operating expenses for the second quarter of 2026 were $57.2 million, up 11% from $51.7 million in the prior year, driven primarily by increased general and administrative costs, which rose by 41% to $10.6 million.

In terms of financial position, as of June 30, 2026, Annexon had cash and cash equivalents totaling $199.3 million, an increase from $162.1 million at the end of 2025. However, total current assets decreased to $212.8 million from $242.2 million, largely due to a significant reduction in short-term investments, which fell from $76.3 million to $10.0 million. The company’s accumulated deficit reached approximately $1.0 billion, reflecting ongoing investments in research and development without any revenue from product sales, as its product candidates remain in clinical trials.

Strategically, Annexon is advancing its late-stage programs, particularly focusing on tanruprubart for Guillain-Barré Syndrome and vonaprument for geographic atrophy associated with age-related macular degeneration. The company has engaged with regulatory bodies, including the European Medicines Agency, for the approval of tanruprubart, which has shown promising results in clinical trials. The ongoing FORWARD study aims to broaden the understanding of tanruprubart's efficacy, while the Phase 3 ARCHER II trial for vonaprument continues to progress with a dual primary endpoint strategy.

Operationally, the company has seen fluctuations in its research and development expenses, which decreased by 11% to $82.4 million for the first half of 2026, primarily due to reduced contract manufacturing costs. General and administrative expenses increased by 24% to $20.9 million, reflecting higher consulting and professional service costs. As of June 30, 2026, the company had approximately 201 million weighted-average shares outstanding, resulting in a net loss per share of $0.28 for the second quarter.

Looking ahead, Annexon anticipates continued losses as it invests in the development of its product candidates. The company projects that its existing cash and cash equivalents will support operations into 2028, but it will require additional financing to achieve its long-term goals. The company is exploring various funding options, including equity offerings and collaborations, to sustain its research and development efforts and navigate the regulatory landscape for its investigational therapies.